The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Kurtoglu Metin since 2024.
This trader's CIK number is 2000284.
At the time of last reporting, Kurtoglu Metin was the Chief Technology Officer of Cartesian Therapeutics, Inc.. (stock ticker symbol RNAC).
Also see all insider trading activities at Cartesian Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | RNAC | 0 | $0 | 4,875 | $81,790 | 0 | $0 |
| 2024 | RNAC | 0 | $0 | 134,721 | $2,441,268 | 134,721 | $189,953 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-06 | RNAC | Sale | 2,458 | 16.83 | 41,373 |
| 2025-01-03 | RNAC | Sale | 2,417 | 16.72 | 40,417 |
| 2024-12-09 | RNAC | Option Ex | 10,763 | 1.41 | 15,175 |
| 2024-12-10 | RNAC | Option Ex | 2,901 | 1.41 | 4,090 |
| 2024-12-09 | RNAC | Sale | 10,763 | 25.55 | 274,973 |
| 2024-12-10 | RNAC | Sale | 2,901 | 24.35 | 70,639 |
| 2024-11-19 | RNAC | Option Ex | 200 | 1.41 | 282 |
| 2024-11-20 | RNAC | Option Ex | 5,700 | 1.41 | 8,036 |
| 2024-11-21 | RNAC | Option Ex | 32,789 | 1.41 | 46,232 |
| 2024-11-19 | RNAC | Sale | 200 | 19.50 | 3,900 |
| 2024-11-20 | RNAC | Sale | 5,700 | 17.68 | 100,798 |
| 2024-11-21 | RNAC | Sale | 32,789 | 16.67 | 546,559 |
| 2024-11-14 | RNAC | Option Ex | 25,900 | 1.41 | 36,519 |
| 2024-11-15 | RNAC | Option Ex | 22,068 | 1.41 | 31,115 |
| 2024-11-14 | RNAC | Sale | 25,900 | 16.70 | 432,452 |
| 2024-11-15 | RNAC | Sale | 22,068 | 17.20 | 379,503 |
| 2024-11-18 | RNAC | Option Ex | 34,400 | 1.41 | 48,504 |
| 2024-11-18 | RNAC | Sale | 34,400 | 18.39 | 632,444 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kurtoglu Metin (Chief Technology Officer of Cartesian Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.